US · Healthcare · Biotechnology
EPS came in at -1.34 against a street estimate of -0.46 — a miss of 191.3%.
Analysts rate AnaptysBio Inc a buy (10 buy, 2 hold, 0 sell out of 12) with an average price target of $89.62.
| Fund | Stake |
|---|---|
| EcoR1 Capital, LLC | 26.61% |
| BlackRock Inc | 5.68% |
| TANG CAPITAL MANAGEMENT LLC | 4.49% |
| Morgan Stanley - Brokerage Accounts | 3.36% |
| State Street Corp | 3.35% |
| Vanguard Capital Management, LLC | 2.88% |
| Affinity Asset Advisors, LLC | 2.79% |
| Sanofi | 2.78% |
| Document | Date |
|---|---|
| Shareholder vote results · Q3 2026 ANAPTYSBIO, INC. - 8-K SUMMARY HEADLINE NUMBERS • Annual shareholder meeting held August 11, 2026 • Company trades on Nasdaq under ticker symbol ANA | 2026-08-11 |
| Reg FD disclosure · Q3 2026 ANAPTYSBIO, INC. – 8-K SUMMARY HEADLINE NUMBERS • No financial data provided in this filing BUSINESS & SEGMENT HIGHLIGHTS • Company is a Delaware- | 2026-07-30 |
| Proxy statement · Q2 2026 ANAPTYSBIO, INC. – PROXY STATEMENT SUMMARY HEADLINE NUMBERS • Record date: June 22, 2026 • Outstanding shares entitled to vote: 29,608,481 common sh | 2026-06-29 |
| Material agreement · Q2 2026 ANAPTYSBIO, INC. - 8-K SUMMARY (June 15, 2026) BUSINESS & SEGMENT HIGHLIGHTS • AnaptysBio entered into a Sublease Agreement on June 15, 2026, to sub | 2026-06-22 |
| Reg FD disclosure · Q2 2026 ANAPTYSBIO, INC. - 8-K SUMMARY HEADLINE NUMBERS • No financial metrics, revenue figures, or numerical results disclosed in this filing • Document da | 2026-05-29 |
| Quarterly report · Q1 2026 ANAPTYSBIO, INC. - 10-Q SUMMARY Q1 2026 (Period Ended March 31, 2026) --- HEADLINE NUMBERS • Cash and cash equivalents: $248.5 million (March 31, 2 | 2026-05-12 |
| Annual report FY2025 ANAPTYSBIO, INC. — 10-K SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Company: AnaptysBio, Inc. (Nasdaq: ANAB), clinical-stage biotech focused on | 2026-03-03 |
| Quarterly report · Q3 2025 ANAPTYSBIO, INC. - Q3 2025 10-Q SUMMARY HEADLINE NUMBERS • Cash position: $109.8 million in cash and equivalents (down from $123.1 million at year-e | 2025-11-04 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Split | 15 : 10 effective Apr 20, 2026 | 2026-04-20 |
| Announcement | Date |
|---|---|
| Board authorizes $100 million stock repurchase plan AnaptysBio announced three significant corporate actions on March 27, 2026. First, the company is proceeding with a spin-off of First Tracks Biotherapeutics into a separate public company. S | 2026-03-27 |
| Spin-off of biopharma operations into separate public company announced AnaptysBio announced plans to separate its business into two public companies by Q2 2026 (possibly late April). The company will split into: (1) AnaptysBio (renamed royalty management compan | 2026-03-03 |
| Board authorizes $100 million stock repurchase plan amendment AnaptysBio announced on November 21, 2025 that its Board of Directors authorized an amendment to expand its stock repurchase program. The company is adding $100 million in repurchase authori | 2025-11-21 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for AnaptysBio Inc — free to start.
Google PlayApp StoreData updated 2026-09-18.